PDGFRB Fusion

CI-VAR-00001241Explore in graph →CIViC 2632

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Childhood B-cell Acute Lymphoblastic Leukemia2unmapped disease
ATF7IP::PDGFRB Fusion	Dasatinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID7129 A 14 month old female with normal karyotype B-ALL was found to have an atypical ATF7IP-PDGFRB fusion. At day 19 of VDLP induction, she achieved partial remission with 6.5% lymphoblasts, and a 40 mg/da… (full text at CIViC) PMID 29133777 · Zhang et al., 2017 · Open in CIViC	civic
ATF7IP::PDGFRB Fusion	Bafetinib + Dasatinib + Imatinib + Nilotinib + Ponatinib + RebastinibSubstitutes	Predictive	D	Supports Sensitivity Response	4	submitted	EID7196 In vitro studies in Ba/F3 murine cells. Cells transduced with tetracycline-inducible ATF7IP-PDGFRB were capable of proliferating in an IL-3-independent manner and had a gene expression pattern overlap…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.